Forzinity (elamipretide) for Barth syndrome
Customize your policy alerts
Sign up for Molina Healthcare Policy C30298-A alerts
Get alerted when Policy C30298-A changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization coverage for Forzinity (elamipretide), a once-daily subcutaneous treatment for patients with genetically confirmed Barth syndrome. It establishes initial and continuation criteria, prescriber and administration requirements, exclusions, and documentation needed for coverage.
The policy establishes new coverage criteria for Forzinity (elamipretide) for Barth syndrome.
Continuation-of-therapy requirements and the expanded access appendix were revised.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.